Overview

Oral LAT8881 in Neuropathic Pain

Status:
Completed

Trial end date:
2020-05-03

Target enrollment:

Participant gender:

Summary

This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.

Phase:

Phase 2

Details

Lead Sponsor:

Lateral Pharma Pty Ltd